What stands behind the label
A molecule's road to medicine status is long and expensive: preclinical work, three phases of clinical trials, a manufacturing quality dossier, registration. Muttenthaler and colleagues map that pipeline in detail in Nature Reviews Drug Discovery. A research peptide hasn't travelled that road — in part or at all.
"Research use only" states exactly that: the material is intended for laboratory work. In a vial, in cell culture, in an instrument. Not in a person.
What the label does NOT mean
It doesn't mean "it's actually fine, we're just not allowed to say so". That's a common reading and it's factually wrong: clinical safety and efficacy data in humans genuinely don't exist for these compounds. The label describes reality; it doesn't hide it.
It's also not an automatic mark of quality or its absence. A research reagent can be synthesised superbly or terribly — the label says nothing about that. Only batch-level analytical documentation speaks to quality.
Our position, without ambiguity
Moscow Peptides materials are reagents for laboratory research. We publish no usage regimens, no "how to take it", no winks. Every catalogue page says this directly, and the research library holds the same line: what's published is what gets said; what isn't, doesn't.
If you need a medicine, you need a doctor and a pharmacy. If you need a research material with honest documentation, you're in the right place. These two needs don't overlap, and we don't pretend they do.
References
- Trends in peptide drug discovery — Nature Reviews Drug Discovery, 20, 309–325 (PMID 33536635; DOI 10.1038/s41573-020-00135-8), 2021.
- Therapeutic peptides: Historical perspectives, current development trends, and future directions — Bioorganic & Medicinal Chemistry, 26(10), 2700–2707 (PMID 28720325; DOI 10.1016/j.bmc.2017.06.052), 2018.